Jubilant	Innovatio	on (USA)	Inc.
Ralance	Sheet as a	t 31 Mar	ch 2018

Balance Sheet as at 31 March 2018		USD	INR (' In Thousands)	USD	INR (' In Thousands)
	Notes	2	As at	2	As at
ACCEPTEC		31 March 2018		1 March 2017	
ASSETS					
Non-current assets Financial assets					
i. Non-current investments	1	6 072 940	205 767	2 221 000	200 000
	2	6,072,840 46,968	395,767 3,061	3,221,098	208,888
Income tax asset (net) Total non-current assets	2			2 221 000	200 000
Total non-current assets	12	6,119,808	398,828	3,221,098	208,888
Current assets					
Financial assets					
i. Trade receivables	3	21,775	1,419	4	_
ii. Cash and cash equivalents	4	169,055	11,017	112,576	7,301
iii. Short-term loans and advances	5	1,970,000	128,385	1,800,000	116,730
iv. Other financial assets	6	38,891	2,535	94,364	6,119
Other current assets	7	740	48	682	44
Total current assets	22	2,200,461	143,404	2,007,622	130,194
Total assets		8,320,269	542,232	5,228,720	339,082
EQUITY AND LIABILITIES					
Equity					
Equity share capital	8	2,975,000	160,038	2,975,000	160,038
Other equity		4,832,829	348,798	1,238,655	113,216
Total Equity		7,807,829	508,836	4,213,655	273,254
I I A DILI ITTICC					
LIABILITIES Current liabilities					
Financial liabilities					
i. Trade payables	9	512,440	33,396	12,033	781
Current tax liabilities	10	212,110	20,070	1,003,032	65,047
Total current liabilities		512,440	33,396	1,015,065	65,828
Total liabilities		512,440	33,396	1,015,065	65,828
Total equity and liabilities	8	8,320,269	542,232	5,228,720	339,082

Rajneesh Gupta

Vice President - Finance

Jubilant Innovation (USA) Inc. Statement of Profit and Loss for the year ended 31 March 2018

		USD	INR (' In Thousands)	USD	INR (' In Thousands)
	Notes		the year ended 31 March 2018		e year ended March 2017
Other income	11	1,286,900	82,869	79,894	5,362
Total income		1,286,900	82,869	79,894	5,362
Expenses					
Other expenses	12	553,667	35,938	532,754	35,706
Total expenses	-	553,667	35,938	532,754	35,706
Profit /(loss) before tax		733,233	46,931	(452,860)	(30,344)
Tax expense					
- Current tax			26	1,003,032	67,382
- Deferred tax (credit)	2	5 - 0	(79)	(936,423)	(62,901)
Total tax expense		4	(53)	66,609	4,481
Profit /(loss) for the year		733,233	46,984	(519,469)	(34,825)
Other comprehensive income Items that will not be reclassified to profit or loss					
Changes in fair value of investments which are classified at fair value through OCI		•	*	(2,644,206)	(177,373)
Items that will be reclassified to profit or loss					
Exchange differences on translation of foreign operations	4	-	4,639	•	(3,299)
Other comprehensive income for the year, net of tax		8.5	4,639	(2,644,206)	(180,672)
Total comprehensive income for the year		733,233	51,623	(3,163,675)	(215,497)

Rajneesh Gupta Vice President - Finance

				USD
	Capital reserve	Retained earnings	Equity instruments through OCI	Total
As at 1 April 2016	A.	(1,472,222)	5,874,552	4,402,330
Loss for the year		(519,469)		(519,469)
Equity Instrument through OCI		*	(2,644,206)	(2,644,206)
As at 31 March 2017	*	(1,991,691)	3,230,346	1,238,655
Profit for the year	5	733,233	×	733,233
Addition during the year	2,860,941			2,860,941
As at 31 March 2018	2,860,941	(1,258,458)	3,230,346	4,832,829

INR (' In Thousands)

					i nousanus)
	Capital reserve	Retained earnings	Equity instruments through OCI	Foreign currency translation reserve	Total
As at 1 April 2016		(71,439)	395,769	4,383	328,713
Loss for the year		(34,825)			(34,825)
Exchange loss during the year on translation of foreign operations	×	96		(3,299)	(3,299)
Equity Instrument through OCI	2	120	(177,373)	9	(177,373)
As at 31 March 2017		(106,264)	218,396	1,084	113,216
Profit for the year	=	46,984	-	=	46,984
Exchange gain during the year on translation of foreign operations	ē	120	3	4,639	4,639
Addition during the year	183,959	300	*	31	183,959
As at 31 March 2018	183,959	(59,280)	218,396	5,723	348,798

Rajneesh Gupta Vice President - Finance

Jubilant Innovation (USA) Inc. Statement of Cash Flows for the year ended 31 March 2018

	e year ended March 2018 46,931		e year ended March 2017
-	46,931	(452 gcm	
-	46,931	(452 Q60)	
(60,385)		(432,000)	(30,344)
(60.385)			
(, , ,	(3,894)	(79,894)	(5,362)
9,199	678	74	<u> </u>
8,325	539	2.5	-
(1,226,515)	(78,975)	(4)	~
(536,143)	(34,721)	(532,754)	(35,706)
(21,833)	(1,409)	(14,494)	(972)
492,082	31,764	(500,546)	(33,567)
(65,894)	(4,366)	(1,047,794)	(70,245)
(1,050,000)	(67,778)	-	
(1,115,894)	(72,144)	(1,047,794)	(70,245)
1,226,515	78,975	(1.675,000)	(112,326)
			(120,708)
1,056,515	68,002	(3,475,000)	(233,034)
115,858	7,479	200	42
115,858	7,479	(7 2	(-
7	379	-	3,487
56,479	3,716	(4,522,794)	(299,792)
112,576	7,301	4,635,370	307,093
169,055	11,017	112,576	7,301
	(1,226,515) (536,143) (21,833) 492,082 (65,894) (1,050,000) (1,115,894) 1,226,515 (170,000) 1,056,515 115,858 115,858	(1,226,515) (78,975) (536,143) (34,721) (21,833) (1,409) 492,082 31,764 (65,894) (4,366) (1,050,000) (67,778) (1,115,894) (72,144) 1,226,515 78,975 (170,000) (10,973) 1,056,515 68,002 115,858 7,479 15,858 7,479 56,479 3,716 112,576 7,301	(1,226,515) (78,975) - (536,143) (34,721) (532,754) (21,833) (1,409) (14,494) 492,082 31,764 (500,546) (65,894) (4,366) (1,047,794) (1,050,000) (67,778) - (1,115,894) (72,144) (1,047,794) 1,226,515 78,975 (1,675,000) (170,000) (10,973) (1,800,000) 1,056,515 68,002 (3,475,000) 115,858 7,479 - - 379 - 56,479 3,716 (4,522,794) 112,576 7,301 4,635,370

Rajneesh Gupta Vice President - Finance

Jubilant Innovation (USA) Inc.

Notes to the financial statements for the year ended 31 March 2018

Note 1: Non-current investments

V	USD	INR (' In Thousands)	USD	INR (' In Thousands)
<u>. </u>		As at 31 March 2018		As at 31 March 2017
Investment in Healthcare Ventures IX,L.P Investment in Jubilant Discovery Services LLC	3,211,899 2,860,941	209,319 186,448	3,221,098	208,888
(31 March 2018: 3,485 Equity shares with no par value) Total Non-current investment	6,072,840	395,767	3,221,098	208,888

Note: During the current year as part of the group restructuring, Drug Discovery and Development Solutions Limited (DDDSL) Singapore transferred its investment in Jubilant Drug Services LLC to Jubilant Innovation USA w.e.f. 4 December 2017

Note 2: Income tax asset (net)

Current Advance income tax 46,968 3,061 - Total income tax assets (net) Note 3: Trade receivables USD INR (' In Thousands) As at 31 March 2018 31 March Unsecured, considered good Trade receivables from related parties 21,775 1,419 -	Note 2. Income tax asset (net)	USD	INR (' In Thousands)	USD	INR (' In Thousands) As at
Advance income tax 46,968 3,061 - Total income tax assets (net) 46,968 3,061 - Note 3: Trade receivables USD INR (' In Thousands) As at 31 March 2018 31 March 2018 Unsecured, considered good Trade receivables from related parties 21,775 1,419 -			31 March 2018		31 March 2017
Total income tax assets (net) 46,968 3,061 INR (' In Thousands) As at 31 March 2018 Unsecured, considered good Trade receivables from related parties 21,775 1,419	Current				
Note 3: Trade receivables USD INR (' In Thousands) As at 31 March 2018 31 March 2018 Unsecured, considered good Trade receivables from related parties 21,775 1,419	Advance income tax	46,968	3,061	7 ± 7	*
USD INR ('In Thousands) USD INR ('In Thousands) Thousands As at 31 March 2018 31 March Unsecured, considered good Trade receivables from related parties 21,775 1,419	Total income tax assets (net)	46,968	3,061		
Unsecured, considered good Trade receivables from related parties USD Thousands) Thousands As at 31 March 2018 31 March 2018 31 March 2018 31 March 2019	Note 3: Trade receivables				
Unsecured, considered good Trade receivables from related parties 21,775 1,419		USD	·	USD	INR († In Thousands)
Unsecured, considered good Trade receivables from related parties 21,775 1,419 -			As at		As at
Trade receivables from related parties 21,775 1,419			31 March 2018		31 March 2017
Trade receivables from related parties 21,775 1,419	Unsecured, considered good				
Total trade receivables 21.775 1.419 -	Trade receivables from related parties	21,775	1,419	()	S4
2001 1100 1001 1001	Total trade receivables	21,775	1,419	(e)	

Jubilant Innovation (USA) Inc.

Notes to the financial statements for the year ended 31 March 2018

Note 4: Cash and cash equivalents

Note 4: Cash and cash equivalents		#3/F0 // #		TNID 41 F
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
		As at		As at
		31 March 2018		31 March 2017
Balances with banks				
In current accounts	169,055	11,017	112,576	7,301
Total cash and cash equivalents	169,055	11,017	112,576	7,301
Note 5: Short term loans and advances		FRIED (4 F		INID (1)
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
		As at		As at
		31 March 2018		31 March 2017
(Unsecured and considered good)				
- Loans to related parties	1,970,000	128,385	1,800,000	116,730
Total Short term loans and advances	1,970,000	128,385	1,800,000	116,730
Note 6: Other financial assets				
	USD	INR (' In Thousands)	USD	INR (' In Thousands)
		As at		As at
		31 March 2018		31 March 2017
Advances recoverable from related parties	-	-	79,894	5,181
Interest recoverable from related parties	38,891	2,535	14,470	938
Total other financial assets	38,891	2,535	94,364	6,119
Note 7: Other current assets		TNID /LT.		INR (' In
	USD	INR (' In Thousands)	USD	Thousands)
		As at		As at
		31 March 2018		31 March 2017
Prepaid expenses	740	48	682	44
Total other current assets	740	48	682	44
	K			

Jubilant Innovation (USA) Inc. Statement of changes in Equity for the year ended 31 March 2018

Note 8: Share Capital

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
	As	at	As a	it
	31 Mar	ch 2018	31 Marci	1 2017
Issued, Subscribed and Paid up				
2,975 Equity Shares with no par value	2,975,000	160,038	2,975,000	160,038
(31 March 2017: 2,975 equity shares)				
1). Movement in equity share capital				
		No. of shares		INR (' In
	Note		USD	Thousands)
Balance as at 1 April 2016	8	2,975	2,975,000	160,038
Change in equity share capital during the year			20	
Balance as at 31 March 2017	8	2,975	2,975,000	160,038
Change in equity share capital during the year		-	.8:	-
Balance as at 31 March 2018	8	2,975	2,975,000	160,038

- 2) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.
- 3)During the current year as part of the Group restructuring, Jubilant Innovation BVI Limited transferred its shareholding in the company to Drug Discovery and Development Solutions Limited Singapore(DDDSL) becoming the Holding company w.e.f. 17th November 2017.
- 4) The details of shareholders holding more than 5% shares in the Company:

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
	As	at	As a	t
	31 Marc	h 2018	31 March	2017
	No of shares	% holding in the class	No of shares	% holding in the class
Name of the Shareholder				
Jubilant Innovation BVI Ltd Drug Discovery and Development Solutions Limited	2,975	100%	2,975	100%

Jubilant Innovation (USA) Inc. Notes to the financial statements for the year ended 31 March 2018

Note 9: Trade payables

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
	;	As at 31 March 2018	3	As at 1 March 2017
Trade payables	512,440	33,396	12,033	781
Total trade payables	512,440	33,396	12,033	781

Note 10: Current tax liabilities

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
5-	3	As at 1 March 2018		As at 31 March 2017
Opening balance	1,003,032	65,047		
Add: Current tax payable for the year Less: Taxes paid	1,003,032	65,047	1,003,032	67,382
Less: Foreign currency translation adjustment Closing balance		-	1,003,032	2,335 65,047

Jubilant Innovation (USA) Inc. Notes to the financial statements for the year ended 31 March 2018 Note 11: Other income

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Particulars	For the year ended 31 March 2018		For the year ended 31 March 2017	
Interest income	60,385	3,894	79,894	5,362
Gain on investment at fair value through P&L	1,226,515	78,975	=	
Total other income	1,286,900	82,869	79,894	5,362

Note 12: Other expenses

•	USD	INR (' In Thousands)	USD	INR (' In Thousands)
Particulars	For the year ended 31 March 2018		For the year ended 31 March 2017	
Rates and taxes	225	15		:=
Receivable balance written off	8,325	539	-	-
Auditors remuneration	74	2	2,727	183
Legal and professional fees	527,271	34,150	506,081	33,917
Bank charges	8,647	556	23,845	1,599
Foreign exchange loss	(-)	-	101	7
Diminution in value of investment	9,199	678		-
Total other expenses	553,667	35,938	532,754	35,706